FARMINGDALE, N.Y.--(BUSINESS WIRE)--July 25, 2006--Misonix, Inc. (Nasdaq: MSON - News), a developer of ultrasonic medical device technology for the treatment of cancer and other chronic health conditions, today announced that it has expanded its European high intensity focused ultrasound (“HIFU”) business with its entry into France. Misonix began its expansion in Europe by acquiring controlling interest in its UK distributor, UK-HIFU Limited, in April 2006. In both markets Misonix is selling or making available on a fee-per-use basis the Sonablate® 500 for Visually Directed HIFU treatment of prostate cancer. The Sonablate 500 (“SB500") is a medical device developed by Focus Surgery, Inc. and manufactured and distributed in Europe by Misonix. In addition to applying HIFU to prostate cancer, Misonix has the right to utilize the same technology for treatment of tissue in the kidney, liver and breast.
